Ken Griffin Adaptive Biotechnologies Corp Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$2.34 - $3.96 $11,934 - $20,196	5,100 Added 49.04%	15,500 $56,000
Q1 2024 May 15, 2024	SELL	$2.88 - $4.8 $6,912 - $11,520	-2,400 Reduced 18.75%	10,400 $33,000
Q4 2023 Feb 14, 2024	BUY	$3.46 - $5.33 $10,034 - $15,457	2,900 Added 29.29%	12,800 $62,000
Q3 2023 Nov 14, 2023	SELL	$5.07 - $8.44 $20,280 - $33,760	-4,000 Reduced 28.78%	9,900 $53,000
Q2 2023 Aug 14, 2023	BUY	$6.19 - $8.78 $22,284 - $31,607	3,600 Added 34.95%	13,900 $93,000
Q1 2023 May 15, 2023	SELL	$7.8 - $10.11 $42,900 - $55,605	-5,500 Reduced 34.81%	10,300 $90,000
Q4 2022 Feb 14, 2023	SELL	$6.26 - $9.34 $120,192 - $179,328	-19,200 Reduced 54.86%	15,800 $120,000
Q3 2022 Nov 14, 2022	SELL	$6.5 - $12.67 $46,150 - $89,957	-7,100 Reduced 16.86%	35,000 $249,000

193

153M

8.4K

56K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $847M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.